Streptococcus Pneumoniae Serotype 22F Conjugate Vaccine
This is a pneumococcal vaccine component targeting Streptococcus pneumoniae serotype 22f. It is a conjugate vaccine that links the capsular polysaccharide antigen of serotype 22f to the diphtheria CRM197 protein carrier to enhance immunogenicity. Such conjugate vaccines are designed to induce protective immunity against pneumococcal disease caused by this specific serotype.
A pneumococcal conjugate vaccine component targeting serotype 22f, designed to prevent infections caused by this Streptococcus pneumoniae strain.
Key facts at a glance
- RxNorm
- 2566297
- Generic
- Streptococcus Pneumoniae Serotype 22f Capsular Antigen Diphtheria Crm197 Protein Conjugate Vaccine
- Class
- unclassified
- Brands
- Prevnar 20, Vaxneuvance, Capvaxive
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
This vaccine component is intended to provide protection against Streptococcus pneumoniae serotype 22f, which is associated with invasive pneumococcal disease, pneumonia, and other respiratory infections. It may be used as part of a broader pneumococcal vaccination strategy.
The vaccine works by presenting the capsular polysaccharide antigen from S. pneumoniae serotype 22f conjugated to the non-toxic CRM197 diphtheria protein carrier. This conjugation converts a T-cell independent antigen into a T-cell dependent antigen, enhancing the immune response and generating immunologic memory.
Conjugate vaccines like this are particularly beneficial for young children whose immune systems respond poorly to polysaccharide antigens alone. Safety and efficacy data for the specific formulation should be consulted. As a single-serotype component, this would typically be combined with other serotype antigens in a multivalent vaccine.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 30, 2026. · Read our editorial policy